Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2)
Not Applicable
Completed
- Conditions
- Type2 Diabetes
- Registration Number
- JPRN-UMIN000008944
- Lead Sponsor
- Department of Medicine, Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe hepatic dysfunction(ALT or AST more than 2.5times of normal value) 2)undergo dialysis 3)NYHA Classification:3or4 4)pregnancy 5)past history of the allergy to Vildagliptin 6)severe infection, before and after operation, severe trauma 7)patients who need insulin therapy 8)patients who are judged to be ineligible by the investigator for some reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference in clinical features among the successful patients
- Secondary Outcome Measures
Name Time Method 1) beta-cell function determined by meal tolerance test 2) incidence of adverse event 3) change in the questionnaire about QOL 4) cost benefit 5) HbA1c and continuation of Vildagliptin at 3 and 6 month after admission